Gland Pharma Limited (GLAND) - Total Liabilities

Latest as of March 2026: Rs21.53 Billion INR ≈ $232.83 Million USD

Based on the latest financial reports, Gland Pharma Limited (GLAND) has total liabilities worth Rs21.53 Billion INR (≈ $232.83 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Gland Pharma Limited (GLAND) net asset momentum to track the company's year-over-year net asset growth rate.

Gland Pharma Limited - Total Liabilities Trend (2017–2026)

This chart illustrates how Gland Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. See GLAND FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Gland Pharma Limited Competitors by Total Liabilities

The table below lists competitors of Gland Pharma Limited ranked by their total liabilities.

Company	Country	Total Liabilities
ExlService Holdings Inc NASDAQ:EXLS	USA	$897.58 Million
Bumrungrad Hospital Public Company Limited BK:BH-R	Thailand	฿4.80 Billion
Hyundai Motor Co Pref KO:005387	Korea	₩229.09 Trillion
Appfolio Inc NASDAQ:APPF	USA	$110.33 Million
Golar LNG Limited NASDAQ:GLNG	USA	$3.26 Billion
GEM CO. LTD SP.GDR/10 A F:3730	Germany	€48.41 Billion
Taiwan High Speed Rail Corp TW:2633	Taiwan	NT$320.53 Billion
Axiata Group Bhd KLSE:6888	Malaysia	RM25.63 Billion

Liability Composition Analysis (2017–2026)

This chart breaks down Gland Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GLAND company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.68	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.21	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.17	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Gland Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Gland Pharma Limited (2017–2026)

The table below shows the annual total liabilities of Gland Pharma Limited from 2017 to 2026.

Year	Total Liabilities	Change
2026-03-31	Rs21.53 Billion ≈ $232.83 Million	+3.80%
2025-03-31	Rs20.74 Billion ≈ $224.31 Million	+7.06%
2024-03-31	Rs19.37 Billion ≈ $209.52 Million	+136.61%
2023-03-31	Rs8.19 Billion ≈ $88.55 Million	+21.13%
2022-03-31	Rs6.76 Billion ≈ $73.11 Million	+14.03%
2021-03-31	Rs5.93 Billion ≈ $64.11 Million	+34.80%
2020-03-31	Rs4.40 Billion ≈ $47.56 Million	-33.52%
2019-03-31	Rs6.62 Billion ≈ $71.54 Million	+27.44%
2018-03-31	Rs5.19 Billion ≈ $56.14 Million	+35.21%
2017-03-31	Rs3.84 Billion ≈ $41.52 Million	--

About Gland Pharma Limited

NSE:GLAND India Drug Manufacturers - Specialty & Generic

Market Cap

$4.60 Billion

Rs425.46 Billion INR

Market Cap Rank

#3735 Global

#167 in India

Share Price

Rs2579.20

Change (1 day)

+3.05%

52-Week Range

Rs1596.80 - Rs2579.20

All Time High

Rs4272.42